M&A Acquirer Playbook

TransMedics Group, Inc. acquisition history.

Every deal, price, and strategic rationale.

Company TransMedics Group, Inc.
SEC CIK 0001756262
Tracked filings EDGAR · 8-K
Total deals tracked
2
Disclosed 8-K acquisitions, 2023 — present.
Aggregate disclosed value
$42M
approximately $42 million across disclosed transactions ($14.9M Summit consideration plus $27.2M Bridge to Life IPR&D).
Active acquisition years
2023
both disclosed acquisitions closed within two weeks of each other.
Primary sectors
Transplant logistics and organ-perfusion technology
Summit Aviation (charter aviation for the National OCS Program) and Bridge to Life / Tevosol (lung and heart perfusion IPR&D).
Verified 2 deals on this page · sourced from SEC filings
All cross-references covered.
Timeline

2 deals, $42M deployed.

Plotted by close date where disclosed, otherwise announcement. Click any marker to jump to the deal entry.

2024 2026 $14.9M Aug 2023 Summit Aviation, Inc. (… $27.2M Aug 2023 Bridge to Life Ltd. / T…
The playbook

The rationale that repeats.

Three patterns show up across TransMedics's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the individual deals below are the evidence.

01
Acquisition criteria

Vertical integration of organ logistics.

TransMedics did not buy another medtech company — it bought a charter airline. The Summit Aviation acquisition let it establish TransMedics Aviation as "the first integrated national provider of air logistics dedicated exclusively to organ transplantation in the U.S.," part of management strategy "to build and manage a national transplant logistics network designed to expand the reach and coverage of the National OCS Program (NOP)."

Summit Aviation, Inc. (and Northside Property Group, LLC)Bridge to Life Ltd. / Tevosol, Inc. (lung and heart perfusion technology assets)
02
Capital deployment

Buying technology, not revenue.

The Bridge to Life / Tevosol deal was structured as an asset acquisition rather than a business combination, with substantially all value concentrated in a single lung-and-heart perfusion IPR&D asset. The $27.2 million was expensed immediately as R&D, signaling a bet on future indications rather than near-term revenue: TransMedics "intends to further develop these technologies to expand its product offerings and indications for organ transplantation."

Summit Aviation, Inc. (and Northside Property Group, LLC)Bridge to Life Ltd. / Tevosol, Inc. (lung and heart perfusion technology assets)
03
Integration approach

First-time acquirer building capabilities it had never operated.

TransMedics own FY23 10-K calls Summit and Bridge to Life "the Company’s first acquisitions," and flags that it "never provided aviation transportation services prior to the acquisition" and will "depend on the management team of Summit." Both deals closed in August 2023, soon after the company’s 2022 CIBC credit facility was amended to permit acquisitions.

Summit Aviation, Inc. (and Northside Property Group, LLC)Bridge to Life Ltd. / Tevosol, Inc. (lung and heart perfusion technology assets)
Deal book · 2 acquisitions

The full deal book.

2 acquisitions. Click any row to see the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.

End of deal book
2 acquisitions · $42M deployed ·2023 — present
VectorShift for deal teams

Put VectorShift to work
on every deal.

VectorShift reads the documents your team actually works on — CIMs, management decks, filings, expert calls, portfolio reports — and returns structured, sourced analysis in minutes, not weeks.

Request a demo